Redhill Biopharma

Update in progress

RDHL (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

RedHill Biopharma Ltd. is a specialty biopharmaceutical company based in Tel Aviv-Yafo, Israel. It develops and markets GI and infectious-disease therapies, including Talicia for H. pylori and Aemcolo for travelers’ diarrhea in adults. Its pipeline features five candidates: opaganib for severe COVID-19 pneumonia; RHB-107 (upamostat) for outpatient SARS-CoV-2 infection and cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for acute gastroenteritis/IBS-D and anti-emetic use; and RHB-204 for pulmonary MAC disease.

Company score

Sentiment: 0.37; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.26; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive